ePRO Global Innovator PHT Corporation Appoints David Avakian as Chief Architect

PHT ePRO Systems are widely acclaimed to improve safety, quality and efficiencies in the collection of clinical trial subject data.

BOSTON & GENEVA--(BUSINESS WIRE)--PHT Corporation continues to attract the clinical trial industry's most esteemed executives. PHT announced today that David Avakian joined the company as Chief Architect. For more than 20 years Mr. Avakian has managed cross-functional teams to create mission critical, scalable enterprise software for global applications. Prior to PHT, Mr. Avakian worked at Phase Forward where he was responsible for several products in the clinical space including Oracle's Health Sciences Trial Center and Central CodingTM.

"PHT continues to raise the bar in delivering ePRO Systems that dramatically improve the process used by sponsors and CROs to collect clinical trial data. I'm proud to join such a high caliber team that ultimately helps bring new drugs and therapies to market quicker, safely, and economically."

As Chief Architect, Mr. Avakian leads the innovative design process for software, systems and infrastructure of the PHT PRO System. PHT Vice President of Product Development Elizabeth Ricci commented, "David has a natural ability and eye for modularity, performance, and scalability while adhering to good coding best practices and leveraging the latest technical tools. What set's David apart is his ability to balance architecture with business needs - a critical factor in meeting PHT's goals while ensuring service delivery and customer satisfaction."

PHT President and CEO Philip Lee added, "David has earned a global reputation for his ability to conceptualize and research architecture and implementation strategies that span technologies and enterprises. His addition to our world-class team will help to continue PHT's dominance as the global leader in ePRO Systems."

Mr. Avakian commented, "PHT continues to raise the bar in delivering ePRO Systems that dramatically improve the process used by sponsors and CROs to collect clinical trial data. I'm proud to join such a high caliber team that ultimately helps bring new drugs and therapies to market quicker, safely, and economically."

About PHT Corporation

PHT Corporation is the industry's only dedicated full-service ePRO provider. PHT offers clients a comprehensive solution for acquiring, managing and analyzing data collected directly from patients through all phases of clinical development. More than 115 biopharmaceutical companies use PHT's ePRO System to easily collect high quality, regulatory compliant clinical trial data. PHT's proven LogPad®, NetPROTM and versatile SitePad® Systems deliver the voice of the patient, in 88 languages, from homes and sites in 67 countries around the world. Patient experiences captured firsthand by PHT's ePRO System have been used successfully in at least 18 regulatory submissions and 16 approvals to date resulting in 14 PRO-based label claims for sponsors. For more information on PRO and ePRO innovations, review the interactive content and demonstrations at phtcorp.com. Follow PHT on Twitter.

PHT is a registered trademark of PHT Corporation. Central CodingTM is a registered trademark of Oracle.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50043075&lang=en
Contacts

PHT Corporation
Brenda Nashawaty, 617-688-3253
[email protected]

 

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.